THERE'S MORE TO MIGRAINE
Vydura (rimegepant)1,2
This patient website is only intended for patients who have been prescribed rimegepant and it is not intended to replace the Patient Information Leaflet provided inside your medication pack.
Therefore, patients are advised to read the Patient Information Leaflet before beginning treatment.
Reporting of side effects: If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.
What is Rimegepant and what is it for?
Rimegepant is indicated for:
Acute treatment of migraine with or without aura in adults
Preventative treatment of episodic migraines in adults who have at least 4 migraine attacks per month
Rimegepant comes as a wafer (known as an oral lyophilisate) that dissolves when placed on the tongue or under the tongue as per SPC
During migraine attacks, you may have increased levels of a substance called calcitonin gene-related peptide (CGRP) in your body. CGRP binds to specific receptors resulting in migraine.
Rimegepant attaches to the CGRP receptor and reduces the activity of CGRP by that, and can:
Stop an active migraine attack
Decrease the number of migraine attacks that occur when taken preventively
What is Rimegepant and what is it for?
Rimegepant is indicated for:
Acute treatment of migraine with or without aura in adults
Preventative treatment of episodic migraines in adults who have at least 4 migraine attacks per month
Rimegepant comes as a wafer (known as an oral lyophilisate) that dissolves when placed on the tongue or under the tongue as per SPC
During migraine attacks, you may have increased levels of a substance called calcitonin gene-related peptide (CGRP) in your body. CGRP binds to specific receptors resulting in migraine.
Rimegepant attaches to the CGRP receptor and reduces the activity of CGRP by that, and can:
Stop an active migraine attack
Decrease the number of migraine attacks that occur when taken preventively
How to take this medicine?
Rimegepant is an oral medication that dissolves on the tongue or under the tongue. It can be taken with or without water. You do not need to take it with food.
Recommended dosing for treating a migraine attack
Recommended dosing for the prevention of migraine
Instructions on how to take this medicine
Treating a migraine attack
To treat a migraine attack once it has started, the recommended dose is one oral lyophilisate (75 mg rimegepant) as needed, not more than once daily.
The maximum daily dose is one oral lyophilisate (75mg rimegepant) per day. Do not store the medication outside the blister for future use.
Prevention of migraine
For the prevention of migraine, the recommended dose is one oral lyphilisate (75mg rimegepant) every other day.
The maximum daily dose is one oral lyophilisate (75mg rimegepant) per day. Do not store the medication outside the blister for future use.
Instructions for taking this medicine
Using dry hands, peel back the foil covering of one blister and gently remove the lyophilisate. Do NOT push it through the foil.
Remove it straight away and place it on or under the tongue where it will dissolve. No drink or water is needed.
If you take more rimegepant than you should, talk to your doctor or pharmacist, or go to hospital straight away. Take the medicine pack with you.
If you have any further questions about how to use rimegepant, ask your doctor or pharmacist.
Why did your doctor prescribe you rimegepant?
Doctors consider a range of factors when deciding the right treatment for you, such as:
Any other condition you may have
Any other medication you are currently taking or may need to take in the future
Do not take this medication if you are allergic to rimegepant (active substance) or any of the ingredients listed below
- Gelatin
- Mannitol
- Mint flavour
- Sucralose
Stop taking rimegepant and tell your doctor immediately if you experience any symptoms that could indicate an allergic reaction, e.g., trouble breathing or severe rash. These symptoms can occur several days after administration.
Talk to your doctor or pharmacist if you have:
- Sever liver problems
- Reduced kidney functions or are on kidney dialysis
Some medicines may affect the way rimegepant works or vice versa. Tell your doctor if you have taken, are currently taking, or plan to take any other medicines, including:
- itraconazole and clarithromycin (medicines used to treat fungal or bacterial infections):
- ritonavir and efavirenz (medicines to treat HIV infections)
- bosentain (a medicine used to treat high blood pressure)
- St. John's wort (a herbal remedy used to treat prescription)
- phenobarbital (a medicine used to treat epilepsy)
- rifampicin (a medicine used to treat tuberculosis)
- modafinil (a medicine used to treat narcolepsy)
Do not take (rimegepant) more than once every 48 hours if you are also taking:
- fluconazole and erthomicin (for fungal or bacterial infections)
- diltiazem, quinidine and verapimil (for abnormal heart rhythm, chest pain (angina), or high blood pressure)
- cyclosporin (a medicine used to prevent organ rejection after an organ transplant)
Like all medicines, rimegepant can cause side effects, although not everybody gets them.
- Stop taking rimegepant and contact your doctor straight away if you have signs of an allergic reaction such as severe rash or shortness of breath. Allergic recations with rimegepant are uncommon (may affect up to 1 in 100 people)
- Nausea is a common side effect (may affect up to 1 in 10 people)
Reporting of side effects: if you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.
If you are pregnant, may be pregnant, or planning to have a baby, ask your doctor or pharmacist for advice before taking your medication, as the effects of this medicine in pregnant women are not known.
If you are breastfeeding or are planning to breastfeed, talk to your doctor or pharmacist before using this medicine. You and your doctor should decide if you will use rimegepant while breastfeeding.
References:
1. Vydura (rimegepant) Summary of Product Characteristics for Great Britain; Vydura (rimegepant) Summary of Product Characteristics for Northern Ireland.
2. Vydura (rimegepant) Patient Information Leaflet for Great Britain; Vydura (rimegepant) Patient Information Leaflet for Northern Ireland.
PP-NNT-GBR-0264. June 2024.